Articles

MDoutlook® Delivers Precision Intelligence

Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages. Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares
Read more
Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today. ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare
Read more
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019. The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where
Read more
MDoutlook empowers confident business decisions with valuable precision insights and actionable intelligence. At the recent 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at
Read more
ImmunoOncology (IO) expands the treatment possibilities and provides substantial clinical benefit, especially in patients who had little to no effective treatment options less than a decade ago. IO features prominently at the 2019 annual European Society for Medical Oncology (ESMO) annual congress in Barcelona where agenda items will cover topics
Read more
In today’s climate, the imperative for new products or brands to achieve their full potential quickly has never been greater. Key to achieving success is measuring and communicating progress, both internally and externally. Tracking your product is an iterative process of measuring, managing and monitoring key performance indicators (KPIs) for
Read more
Increasingly, biopharmaceutical companies recognize the importance and value of identifying and engaging ‘rising stars’ since they are typically younger, tech-engaged, offer novel perspectives, future ThoughtLeaders and a window to tomorrow’s healthcare market. Similarly, clients are increasingly using MDoutlook precision intelligence to identify the most relevant rising star ThoughtLeaders (TL; also
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them. Even with these CLL presentations being on the
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC
Read more
Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages. Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares
Read more
Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today. ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare
Read more
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019. The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where
Read more
MDoutlook empowers confident business decisions with valuable precision insights and actionable intelligence. At the recent 2019 annual meeting of the Association of Residents in Radiation Oncology (ASTRO), one of our clients was interested in recruiting very specific radiation oncologists (recruited to a very tight inclusion criteria) to an event at
Read more
ImmunoOncology (IO) expands the treatment possibilities and provides substantial clinical benefit, especially in patients who had little to no effective treatment options less than a decade ago. IO features prominently at the 2019 annual European Society for Medical Oncology (ESMO) annual congress in Barcelona where agenda items will cover topics
Read more
In today’s climate, the imperative for new products or brands to achieve their full potential quickly has never been greater. Key to achieving success is measuring and communicating progress, both internally and externally. Tracking your product is an iterative process of measuring, managing and monitoring key performance indicators (KPIs) for
Read more
Increasingly, biopharmaceutical companies recognize the importance and value of identifying and engaging ‘rising stars’ since they are typically younger, tech-engaged, offer novel perspectives, future ThoughtLeaders and a window to tomorrow’s healthcare market. Similarly, clients are increasingly using MDoutlook precision intelligence to identify the most relevant rising star ThoughtLeaders (TL; also
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them. Even with these CLL presentations being on the
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 2nd OncoPoll™ study following the 2019 ASCO conference, we researched what US and EU5 oncologists thought about a number of new agents being developed that target specific driver mutations in small populations of
Read more
After every major conference, MDoutlook provides valuable insights on the impact of new data presented. At the 2019 ASCO conference, prostate cancer was one of the hottest areas, and our 1st independent OncoPoll™ study researched how clinicians will be treating the non-metastatic castration-resistant and the metastatic hormone-sensitive prostate cancer (nmCRPC
Read more